Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2012

View Archived Issues

NKP-2235 shows unique cytotoxicity profile and synergistic activity with other anticancer agents

Recombinant vectors targeting NY-ESO-1 assessed in phase II trials

First HSP 90-alpha-binding agent with promising antiglaucoma activity

The Arizona Biomedical Research Commission prepares novel EGFR-based peptides

Astellas Pharma reflects on accomplishments of fiscal 2011

New biomarker for measuring disease severity in patients with diabetic retinopathy

StarGen gene therapy being tested in phase I/II clinical trial

German team discloses novel voltage-gated potassium channel modulators

Ono Pharmaceutical recaps events of fourth quarter 2011

Biota Scientific Management prepares new antiviral agents

Researchers at Merck & Co. report new series of phosphodiesterase 10A inhibitors

Blood glucose-lowering agents patented by Daiichi Sankyo

Novel IL-17 production inhibitors synthesized by Japanese group

Novelos Therapeutics provides update on HOT radiotherapeutic agent

Theraclone Sciences reports topline phase I TCN-032 study data

FDA approves TG Therapeutics' IND for phase I/II ublituximab study

Celsion and Philips Healthcare resubmit IND for ThermoDox combination study

NIDA grant supports Scripps Research Institute smoking cessation research

Cardiac function improves in preclinical study of PLX cells

ACH-3102 receives FDA fast track designation for the treatment of HCV

Phase I/IIa trial begins for Aes-103 in sickle cell disease

GSK to acquire Cellzome

Innova Biosciences awarded grant to develop nanoparticle products

Phase I/II trials begins of combination therapy for advanced metastatic melanoma

Juventas opens enrollment in phase IIa study of JVS-100

Medtronic's Resolute Integrity stent receives approval in new indications in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...